We compared 10 different p-tau assays for detection of amyloid pathology (important for anti-amyloid immunotherapies) and progression to AD dementia (important for prognosis). The results are clear; p-tau217 is the best p-tau biomarker in symptomatic AD, independent of method.
Janelidze et al. test 10 plasma phospho-tau assays head-to-head for their ability to detect abnormal brain amyloid-β status and predict future progression to Alzheimer's dementia in individuals with mild cognitive impairment.
bit.ly/3opUmfv